시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 살부타몰 원료의약품(API) 시장 보고서(2025년)
Salbutamol active pharmaceutical ingredient (API) Global Market Report 2025
상품코드 : 1769740
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

살부타몰 원료의약품(API) 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.4%로 39억 달러로 성장할 것으로 예상됩니다. 예상되는 성장의 배경으로는 대기 환경 악화, 천식 및 COPD 이환율 증가, 제네릭 의약품 수요 증가, 건강 관리 지출 증가, 건강 관리 인프라 개발 등이 있습니다. 향후 수년간 예상되는 현저한 동향으로는 친환경 화학 공정의 진보, 자동화 생산 시스템의 채택 확대, 공정 분석 기술(PAT)의 이용 강화, 정량 흡입기 기술의 혁신, 개별 투여 형식의 출현 등을 들 수 있습니다.

호흡기 질환의 이환율 상승은 향후 수년간 살부타몰 원료의약품(API) 시장의 성장을 이끌 것으로 예측됩니다. 호흡기 질환은 폐와 기도에 영향을 미치고 호흡 곤란과 산소 섭취량의 감소로 이어집니다. 이 질병에는 천식, 만성 폐색성 폐 질환(COPD), 폐렴, 기관지염 및 기타 폐 감염이 포함됩니다. 호흡기 질환 환자 수 증가는 기도에 자극을 주고 폐 기능을 손상시키는 유해한 오염 물질에 개인을 노출시키는 대기 오염 증가로 인해 크게 발생합니다. 살부타몰 원료의약품(API)은 호흡기의 개방을 돕고, 천명과 호흡 곤란 등의 증상을 신속하게 완화하고, 전체적인 호흡 기능과 환자의 건강을 개선함으로써 이러한 증상의 치료에 중요한 역할을 합니다. 예를 들어, 2024년 11월에 호주 통계국이 발표한 바에 따르면, 2022년에는 약 280만 명의 호주인(인구의 약 11%)이 천식 환자였습니다. 천식은 2023년에는 전 질환 부담의 2.5%, 호흡기 질환 부담의 35%를 차지하며, 1-9세의 소아의 질환 부담의 주된 원인이 되고 있습니다. 그 결과 호흡기 질환의 유병률 증가가 살부타몰 원료의약품(API) 수요에 박차를 가하고 있습니다.

살부타몰 원료의약품(API) 시장에서 사업을 전개하는 기업은 환경 기준에 맞게 지속 가능한 치료 솔루션을 제공하기 위해 환경 친화적인 흡입기와 같은 혁신적인 약제 제제에 점점 더 주력하고 있습니다. 이러한 흡입기는 지구 온난화 계수가 낮은 추진제를 이용하거나 드라이 파우더 흡입기와 같이 추진제를 사용하지 않는 시스템으로 설계되어 있습니다. GSK plc는 저탄소 흡입기 Ventolin을 3상 시험으로 진행했습니다. 이 흡입기는 배출량을 90% 줄이는 차세대 추진제를 사용하고 있습니다. 기계의 문제를 완화하기 위해 기도를 여는 것으로 작용합니다. 회사의 지속가능성 이니셔티브는 유효성분인 살부타몰 원료의약품(API)은 그대로 흡입기에 사용되는 프로펠런트를 변경하여 환경에 대한 영향을 줄이는 데 중점을 두고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Salbutamol active pharmaceutical ingredient (API) is the pure, pharmacologically active component that delivers the intended therapeutic effect in medications used for treating respiratory disorders. It serves as the foundational compound utilized by pharmaceutical manufacturers in producing finished dosage forms such as inhalers, tablets, and syrups.

The primary variants of salbutamol active pharmaceutical ingredient (API) include salbutamol sulfate and levalbuterol hydrochloride. Salbutamol sulfate, the sulfate salt form of salbutamol, acts as a rapid-onset bronchodilator, alleviating symptoms of asthma and other obstructive airway conditions by relaxing airway muscles. These APIs are formulated into inhalation solutions, tablets, syrups, and other dosage forms and are made available through hospital pharmacies, retail pharmacies, and online platforms. They are indicated for conditions such as asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, among others, and are used by end-users like pharmaceutical companies, research institutions, and others.

The salbutamol active pharmaceutical ingredient (API) market research report is one of a series of new reports from The Business Research Company that provides salbutamol active pharmaceutical ingredient (API) market statistics, including the salbutamol industry global market size, regional shares, competitors with the salbutamol active pharmaceutical ingredient (API) market share, detailed salbutamol active pharmaceutical ingredient (API) market segments, market trends, and opportunities, and any further data you may need to thrive in the salbutamol active pharmaceutical ingredient (API) industry. This salbutamol active pharmaceutical ingredient (API) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The salbutamol active pharmaceutical ingredient (API) market size has grown strongly in recent years. It will grow from $2.86 billion in 2024 to $3.05 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The expansion during the historical period was supported by a growing prevalence of respiratory illnesses, an aging demographic, increased availability of generic medications, a rise in healthcare infrastructure, and heightened levels of environmental pollution.

The salbutamol active pharmaceutical ingredient (API) market size is expected to see strong growth in the next few years. It will grow to $3.90 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The projected growth is attributed to worsening air quality, increasing rates of asthma and COPD, escalating demand for generics, growing healthcare spending, and the development of healthcare infrastructure. Prominent trends anticipated in the coming years include progress in eco-friendly chemical processes, greater adoption of automated production systems, enhanced use of process analytical technology (PAT), innovations in metered-dose inhaler technologies, and the emergence of individualized dosing formats.

The rising incidence of respiratory diseases is expected to drive the growth of the salbutamol active pharmaceutical ingredient (API) market in the coming years. Respiratory conditions affect the lungs and airways, leading to breathing difficulties and reduced oxygen intake. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and other lung infections. The growing number of respiratory cases is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and impair lung function. Salbutamol API plays a vital role in treating these conditions by helping to open the airways, providing quick relief from symptoms such as wheezing and shortness of breath, and improving overall respiratory function and patient health. For example, in November 2024, the Australian Bureau of Statistics reported that in 2022, approximately 2.8 million Australians-about 11% of the population-were living with asthma. Asthma accounted for 2.5% of the total disease burden and 35% of the respiratory disease burden in 2023, making it the leading cause of disease burden among children aged 1-9 years. Consequently, the increasing prevalence of respiratory diseases is fueling the demand for salbutamol API.

Companies operating in the salbutamol API market are increasingly focusing on innovative drug formulations, such as eco-friendly inhalers, to align with environmental standards and offer sustainable treatment solutions. These inhalers utilize propellants with low global warming potential or are designed as propellant-free systems, such as dry powder inhalers. For instance, in November 2023, GSK plc, a UK-based pharmaceutical company, advanced its low-carbon Ventolin inhaler to Phase III trials. This inhaler uses a next-generation propellant that reduces emissions by 90%. Ventolin is a brand of inhalers containing salbutamol (also known as albuterol), which works by opening the airways to provide relief from asthma and other respiratory issues. The company's sustainability initiative focuses on modifying the propellant used in the inhaler to reduce its environmental impact, while maintaining the same active ingredient-salbutamol API.

In October 2022, Lupin Limited, an India-based pharmaceutical company, acquired the rights to Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol from Sunovion Pharmaceuticals Inc. for $75 million. This acquisition enhances Lupin's respiratory product portfolio in the US market, strengthening its presence in the inhalation therapy segment and improving its capability to support patients with chronic respiratory conditions. Sunovion Pharmaceuticals Inc. is a US-based firm known for its expertise in respiratory treatments, including those based on the salbutamol active pharmaceutical ingredient (API) for asthma and COPD.

Major players in the salbutamol active pharmaceutical ingredient (api) market are Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Amphastar Pharmaceuticals Inc., FDC Limited, Neuland Laboratories Ltd., Melody Healthcare Pvt. Ltd., Supriya Lifescience Ltd., Lusochimica S.p.A., Intas Pharmaceuticals ltd, Olon S.p.A., VIVAN Life Sciences, Vamsi Labs Ltd., Aarti Pharmalabs Ltd., Jayco Chemical Industries, Orex Pharma Pvt. Ltd., Enomark, Chemcopia, and Cerata Pharma.

North America was the largest region in the salbutamol active pharmaceutical ingredient (API) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in salbutamol active pharmaceutical ingredient (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the salbutamol active pharmaceutical ingredient (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The salbutamol active pharmaceutical ingredient (API) market consists of sales of nebulizer solutions, raw salbutamol powder, and injectable salbutamol formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Salbutamol active pharmaceutical ingredient (API) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on salbutamol active pharmaceutical ingredient (api) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for salbutamol active pharmaceutical ingredient (api) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The salbutamol active pharmaceutical ingredient (api) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Salbutamol Active Pharmaceutical Ingredient (API) Market Characteristics

3. Salbutamol Active Pharmaceutical Ingredient (API) Market Trends And Strategies

4. Salbutamol Active Pharmaceutical Ingredient (API) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Salbutamol Active Pharmaceutical Ingredient (API) Growth Analysis And Strategic Analysis Framework

6. Salbutamol Active Pharmaceutical Ingredient (API) Market Segmentation

7. Salbutamol Active Pharmaceutical Ingredient (API) Market Regional And Country Analysis

8. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market

9. China Salbutamol Active Pharmaceutical Ingredient (API) Market

10. India Salbutamol Active Pharmaceutical Ingredient (API) Market

11. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market

12. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market

13. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market

14. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market

15. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

16. UK Salbutamol Active Pharmaceutical Ingredient (API) Market

17. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market

18. France Salbutamol Active Pharmaceutical Ingredient (API) Market

19. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market

20. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market

21. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

22. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market

23. North America Salbutamol Active Pharmaceutical Ingredient (API) Market

24. USA Salbutamol Active Pharmaceutical Ingredient (API) Market

25. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market

26. South America Salbutamol Active Pharmaceutical Ingredient (API) Market

27. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market

28. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market

29. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market

30. Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Landscape And Company Profiles

31. Salbutamol Active Pharmaceutical Ingredient (API) Market Other Major And Innovative Companies

32. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Salbutamol Active Pharmaceutical Ingredient (API) Market

34. Recent Developments In The Salbutamol Active Pharmaceutical Ingredient (API) Market

35. Salbutamol Active Pharmaceutical Ingredient (API) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기